BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 9759996)

  • 1. Reciprocal expression of bcl-2 and p53 oncoproteins in urothelial dysplasia and carcinoma of the urinary bladder.
    Li B; Kanamaru H; Noriki S; Yamaguchi T; Fukuda M; Okada K
    Urol Res; 1998; 26(4):235-41. PubMed ID: 9759996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prevalence of bcl-2, p53, and Ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlates.
    Nakopoulou L; Vourlakou C; Zervas A; Tzonou A; Gakiopoulou H; Dimopoulos MA
    Hum Pathol; 1998 Feb; 29(2):146-54. PubMed ID: 9490274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of bcl-2 and p53 oncoproteins in schistosomiasis-associated transitional and squamous cell carcinoma of urinary bladder.
    Chaudhary KS; Lu QL; Abel PD; Khandan-Nia N; Shoma AM; el Baz M; Stamp GW; Lalani EN
    Br J Urol; 1997 Jan; 79(1):78-84. PubMed ID: 9043502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variable Bcl-2 phenotype in benign and malignant lesions of urothelium.
    Bilim VN; Tomita Y; Kawasaki T; Takeda M; Takahashi K
    Cancer Lett; 1998 Jun; 128(1):87-92. PubMed ID: 9652797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of p53, MDM2 and bcl-2 expression in transitional cell carcinoma of the bladder.
    Uchida T; Minei S; Gao JP; Wang C; Satoh T; Baba S
    Oncol Rep; 2002; 9(2):253-9. PubMed ID: 11836589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of bcl-2 in bladder neoplasms is a cell lineage associated and p53-independent event.
    Lu QL; Laniado M; Abel PD; Stamp GW; Lalani EN
    Mol Pathol; 1997 Feb; 50(1):28-33. PubMed ID: 9208811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors in transitional cell cancer of the bladder: an emerging role for Bcl-2 and p53.
    Ong F; Moonen LM; Gallee MP; ten Bosch C; Zerp SF; Hart AA; Bartelink H; Verheij M
    Radiother Oncol; 2001 Nov; 61(2):169-75. PubMed ID: 11690683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical analysis of bcl-2 expression in transitional cell carcinoma of the bladder.
    Shiina H; Igawa M; Urakami S; Honda S; Shirakawa H; Ishibe T
    J Clin Pathol; 1996 May; 49(5):395-9. PubMed ID: 8707954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53 protein and Ki-67 overexpression in urothelial dysplasia of bladder.
    Sun W; Zhang PL; Herrera GA
    Appl Immunohistochem Mol Morphol; 2002 Dec; 10(4):327-31. PubMed ID: 12607601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biologic differences between noninvasive papillary urothelial neoplasms of low malignant potential and low-grade (grade 1) papillary carcinomas of the bladder.
    Pich A; Chiusa L; Formiconi A; Galliano D; Bortolin P; Navone R
    Am J Surg Pathol; 2001 Dec; 25(12):1528-33. PubMed ID: 11717543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of survivin does not predict survival in patients with transitional cell carcinoma of the upper urinary tract.
    Nakanishi K; Tominaga S; Hiroi S; Kawai T; Aida S; Kasamatsu H; Aurues T; Hayashi T; Ikeda T
    Virchows Arch; 2002 Dec; 441(6):559-63. PubMed ID: 12461612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. P53 overexpression in bladder urothelial neoplasms: new aspect of World Health Organization/International Society of Urological Pathology classification.
    Kalantari MR; Ahmadnia H
    Urol J; 2007; 4(4):230-3. PubMed ID: 18270948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship of p53 and bcl-2 to prognosis in muscle-invasive transitional cell carcinoma of the bladder.
    Glick SH; Howell LP; White RW
    J Urol; 1996 May; 155(5):1754-7. PubMed ID: 8627878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p53 and bcl-2 overexpression as associated risk factors in patients 40 years old or less with transitional cell carcinoma of the bladder.
    Asci R; Yildiz L; Sarikaya S; Buyukalpelli R; Yilmaz AF; Kandemir B
    Urol Int; 2001; 67(1):34-40. PubMed ID: 11464113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential expression of hepatocyte growth factor in papillary and nodular tumors of the bladder.
    Li B; Kanamaru H; Noriki S; Fukuda M; Okada K
    Int J Urol; 1998 Sep; 5(5):436-40. PubMed ID: 9781430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of bcl-2 and bcl-X in bladder cancer.
    Kirsh EJ; Baunoch DA; Stadler WM
    J Urol; 1998 Apr; 159(4):1348-53. PubMed ID: 9507882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Urothelial hyperplastic lesion with endophytic growth pattern: a clinicopathologic study].
    Xiao L; Wang CF; Zhu XZ; Yin YL; Chen Y; Lu C; Yu B
    Zhonghua Bing Li Xue Za Zhi; 2011 May; 40(5):319-23. PubMed ID: 21756826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bcl-2 and p53 overexpression as associated risk factors in transitional cell carcinoma of the bladder.
    Atuğ F; Türkeri L; Ozyürek M; Akdaş A
    Int Urol Nephrol; 1998; 30(4):455-61. PubMed ID: 9821049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The expression of bcl-2 and bcl-6 protein in normal and malignant transitional epithelium.
    Lin Z; Kim H; Park H; Kim Y; Cheon J; Kim I
    Urol Res; 2003 Aug; 31(4):272-5. PubMed ID: 12879322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
    Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
    Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.